Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Director John B. Landis bought 40,000 shares of the business’s stock in a transaction on Monday, May 13th. The shares were acquired at an average cost of $1.74 per share, for a total transaction of $69,600.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of Eyepoint Pharmaceuticals stock traded down $0.02 on Thursday, reaching $1.81. 5,061 shares of the company were exchanged, compared to its average volume of 398,239. The firm has a market capitalization of $189.93 million, a PE ratio of -3.12 and a beta of 1.89. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.37. Eyepoint Pharmaceuticals Inc has a fifty-two week low of $1.24 and a fifty-two week high of $3.94.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, May 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). The company had revenue of $2.01 million for the quarter, compared to analyst estimates of $3.70 million. Eyepoint Pharmaceuticals had a negative return on equity of 174.26% and a negative net margin of 1,739.81%. Analysts expect that Eyepoint Pharmaceuticals Inc will post -0.4 EPS for the current year.
Several analysts have weighed in on the company. Zacks Investment Research raised Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $4.50 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, May 9th. Finally, ValuEngine downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 21st.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.
Featured Story: Price-Sales Ratio
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.